Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin + Cisplatin in Locally Advanced Cervical Cancer
NCT06558682Recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Oct 2024
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Open-label, single-arm trial of disitamab vedotin in Cervical Cancer (CC), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Pathologic Complete Remission at 9 weeks. Started Oct 2024; status: recruiting.
02
Drugs
disitamab vedotin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06558682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06558682.